ARS Pharmaceuticals, Inc (SPRY) — Cash Flow Quality Index
ARS Pharmaceuticals, Inc (SPRY) has a Cash Flow Quality Index of 0.84x as of December 2024. Operating cash flow of $42.00 Million is below net income of $49.93 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore ARS Pharmaceuticals, Inc cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
ARS Pharmaceuticals, Inc Cash Flow Quality Index (2024–2024)
Historical Cash Flow Quality Index for ARS Pharmaceuticals, Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check ARS Pharmaceuticals, Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for ARS Pharmaceuticals, Inc (2024–2024)
Year-by-year earnings quality comparison for ARS Pharmaceuticals, Inc. For live market cap and the full company financial profile, see ARS Pharmaceuticals, Inc (SPRY) total market value.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.69x | $13.55 Million | $8.00 Million | — |